@article{oai:u-ryukyu.repo.nii.ac.jp:02015564,
 author = {宇野, 司 and Uno, Tsukasa},
 issue = {3・4},
 journal = {琉球医学会誌 = Ryukyu Medical Journal},
 month = {},
 note = {Omeprazole is one of the most widely used proton pump inhibitors for the treatment of gastric acid-related disorders. Omeprazole is completely metabolized, predominantly to 5-hydroxyomeprazole catalyzed by CYP2C19, which shows genetically determined polymorphism, yielding extensive metabolizers(EMs) and poor metabolizers(PMs). The CYP2C19 genetic polymorphism results in a significant difference in the area under the plasma concentration-time curve(AUC）of omeprazole, and AUC of omeprazole in PMs was significantly higher than that in EMs. The CYP2C19 genotyping therefore is a useful tool for guiding treatment effect in patients with various peptic diseases because the acid suppressive effect of omeprazole is also reported to correlate with AUC level. For the better treatment of gastric acid-related disorders, doses and dosing schemes of omeprazole should be optimized based on CYP2C19 genotype status．, 論文},
 pages = {105--112},
 title = {［総説］CYP2C19に関連したomeprazoleの代謝と体内動態について},
 volume = {26},
 year = {2007}
}